Vivas Jeilyn, Ibarra Carlos, Salazar Ana M, Neves-Ferreira Ana G C, Sánchez Elda E, Perales Jonás, Rodríguez-Acosta Alexis, Guerrero Belsy
Laboratorio de Fisiopatología, Centro de Medicina Experimental, Instituto Venezolano de Investigaciones Científicas, Caracas 1020A, Venezuela.
Laboratorio de Toxinologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Comp Biochem Physiol C Toxicol Pharmacol. 2016 Jan;179:107-15. doi: 10.1016/j.cbpc.2015.09.009. Epub 2015 Sep 28.
A plasmin inhibitor, named tenerplasminin-1 (TP1), was isolated from Micrurus tener tener (Mtt) venom. It showed a molecular mass of 6542Da, similarly to Kunitz-type serine peptidase inhibitors. The amidolytic activity of plasmin (0.5nM) on synthetic substrate S-2251 was inhibited by 91% following the incubation with TP1 (1nM). Aprotinin (2nM) used as the positive control of inhibition, reduced the plasmin amidolytic activity by 71%. Plasmin fibrinolytic activity (0.05nM) was inhibited by 67% following incubation with TP1 (0.1nM). The degradation of fibrinogen chains induced by plasmin, trypsin or elastase was inhibited by TP1 at a 1:2, 1:4 and 1:20 enzyme:inhibitor ratio, respectively. On the other hand, the proteolytic activity of crude Mtt venom on fibrinogen chains, previously attributed to metallopeptidases, was not abolished by TP1. The tPA-clot lysis assay showed that TP1 (0.2nM) acts like aprotinin (0.4nM) inducing a delay in lysis time and lysis rate which may be associated with the inhibition of plasmin generated from the endogenous plasminogen activation. TP1 is the first serine protease plasmin-like inhibitor isolated from Mtt snake venom which has been characterized in relation to its mechanism of action, formation of a plasmin:TP1 complex and therapeutic potential as anti-fibrinolytic agent, a biological characteristic of great interest in the field of biomedical research. They could be used to regulate the fibrinolytic system in pathologies such as metastatic cancer, parasitic infections, hemophilia and other hemorrhagic syndromes, in which an intense fibrinolytic activity is observed.
从墨西哥珊瑚蛇(Micrurus tener tener,Mtt)毒液中分离出一种纤溶酶抑制剂,命名为tenerplasminin-1(TP1)。它的分子量为6542Da,与库尼茨型丝氨酸肽酶抑制剂相似。与TP1(1nM)孵育后,纤溶酶(0.5nM)对合成底物S-2251的酰胺水解活性被抑制了91%。用作抑制阳性对照的抑肽酶(2nM)使纤溶酶酰胺水解活性降低了71%。与TP1(0.1nM)孵育后,纤溶酶的纤维蛋白溶解活性(0.05nM)被抑制了67%。TP1分别以1:2、1:4和1:20的酶与抑制剂比例抑制纤溶酶、胰蛋白酶或弹性蛋白酶诱导的纤维蛋白原链降解。另一方面,TP1并未消除先前认为由金属肽酶引起的Mtt粗毒液对纤维蛋白原链的蛋白水解活性。组织型纤溶酶原激活物(tPA)凝块溶解试验表明,TP1(0.2nM)的作用与抑肽酶(0.4nM)相似,会导致溶解时间和溶解速率延迟,这可能与抑制内源性纤溶酶原激活产生的纤溶酶有关。TP1是从Mtt蛇毒中分离出的首个丝氨酸蛋白酶类纤溶酶样抑制剂,已对其作用机制、纤溶酶:TP1复合物的形成以及作为抗纤维蛋白溶解剂的治疗潜力进行了表征,这是生物医学研究领域极具研究价值的生物学特性。它们可用于调节转移性癌症、寄生虫感染、血友病和其他出血综合征等疾病中的纤维蛋白溶解系统,在这些疾病中观察到有强烈的纤维蛋白溶解活性。